|
Session 110-Poster Abstracts
CD4 Cell Responses, Immune Activation, and Low-level Viremia
Wednesday, 2-4 pm; Hall A |
572
 |
High T Cell Immune Activation and Immune Exhaustion among ART-treated Patients with Suboptimal CD4 Recovery Despite Long-term Viral Suppression in an African Cohort
Damalie Nakanjako*1, I Ssewanyana2, H Mayanja-Kizza1, A Kiragga1,3, R Colebunders4, Y Manabe1,3, R Nabatanzi2, M Kamya1, and H Cao5
1Makerere Univ Sch of Med, Kampala, Uganda; 2Joint Clin Res Ctr, Kampala, Uganda; 3Infectious Disease Inst, Kampala, Uganda; 4Inst of Tropical Med, Univ of Antwerp, Belgium; and 5California Dept of Publ Hlth, Richmond, US |
573
|
Increased Levels of CD4+ T Cells Expressing CCR5 during Effective Treatment with MRC
Francesca Cossarini*, A Galli, A Bigoloni, C Vinci, L Galli, S Salpietro, V Spagnuolo, A Lazzarin, A Castagna, and S Nozza
San Raffaele Sci Inst, Milan, Italy |
574
|
Effect of Adding and Removing MVC on Immune Activation in HIV+ Patients on Suppressive ART: Results from ACTG A5256
Timothy Wilkin*1, C Lalama2, A Tenorio3, L Fox4, A Landay3, J McKinnon5, R Gandhi6, J Mellors5, J Currier7, and R Gulick1
1Weill Cornell Med Coll, New York, NY, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Rush Univ Med Ctr, Chicago, IL, US; 4DAIDS, NIAID, NIH, Bethesda, MD, US; 5Univ of Pittsburgh Sch of Med, PA, US; 6Massachusetts Gen Hosp, Boston, US; and 7Univ of California, Los Angeles, US |
575
|
Impact of MVC on Immune Responses to the 2009 Pandemic Influenza A-H1N1v Adjuvanted Vaccine in HIV-1-infected Patients
N Le Corre1,2, A Canestri2, A Krivine3, L Assoumou4, F Rozenberg3, L Schneider2, B Autran1,2, C Katlama2, Amélie Guihot*1,2, and Maraviroc Study Group
1INSERM U945, Paris, France; 2Hosp Pitie-Salpetriere, Paris, France; 3Hosp Cochin-St Vincent de Paul, Paris, France; and 4INSERM U943, Paris, France |
| 576 |
Low-level Viremia below 50 Copies/mL in Treated HIV-infected Patients Predicts Viral Load Rebound above 400 Copies/mL Independently of Adherence Levels
Tomas Doyle*1,2, P Vitiello1,2, C Smith2, V Cambiano2, A Owen3, A Phillips2, and AM Geretti1,2
1Royal Free Hampstead NHS Trust, London, UK; 2Univ Coll London, UK; and 3Univ of Liverpool, UK |
577
|
Factors Associated with Low-level HIV-1 RNA between 20 and 50 Copies/mL in Stable Treated Patients
Charlotte Charpentier*, R Landman, C Laouénan, V Joly, G Hamet, F Damond, F Brun-Vézinet, F Mentré, D Descamps, and P Yeni
Hosp Bichat Claude Bernard, Univ Paris Diderot, Paris, France |
|
